Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
Launched by MEDICAL UNIVERSITY OF GRAZ · Dec 13, 2019
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
Background:
Uveitis is a potentially blinding complication of juvenile idiopathic arthritis (JIA). Treatment remains a substantial challenge, even though the use of tumor necrosis factor (TNF)-α-antagonists has improved visual outcomes substantially. Among these agents, adalimumab has been recently approved for the treatment of non-infectious uveitis and is thus the first biologic disease-modifying anti-rheumatic drug (bDMARD) approved for JIA-associated uveitis. However, some patients do not respond sufficiently or lose response over time. In these cases switching to another biologic DMAR...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • JIA associated Uveitis
- • Treatment failure with adalimumab
- Exclusion Criteria:
- • Uveitis due to other causes
- • Adalimumab Initiation because of non ocular reasons
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials